This regulatory clearance specifically targets adult patients who have developed an estrogen receptor-1 mutation while undergoing aromatase inhibitor and CDK4/6 inhibitor therapy. To facilitate precise treatment, the agency also authorized a companion diagnostic test capable of detecting emerging ESR1 resistance mutations.
In section Market Quotes
FDA Grants Accelerated Approval for AstraZeneca Breast Cancer Therapy
The Food and Drug Administration has granted accelerated approval to AstraZeneca’s Etcamah, a new treatment targeting advanced breast cancer. The medication, known generically as camizestrant, is designed for use in combination with a CDK4/6 inhibitor to address specific genetic mutations in patients battling HR-positive, HER2-negative metastatic disease.
AstraZeneca executive vice president Dave Fredrickson described the drug as a milestone in oncology, noting it is the first medicine of its kind authorized for use in the first-line setting. The company aims to redefine care standards by utilizing circulating tumor DNA to monitor patient responses to this targeted approach.
Comments (0)
No comments yet. Be the first!